Revolutionary Breakthrough: Rick Doblin predicts approval for MDMA assisted therapy in 2024
The world of publicly traded companies is a strange and mysterious beast, full of shadowy figures and hidden agendas. But even in this dark landscape, there are a few bright spots shining through. Companies like COMPASS Pathways, atai Life Sciences, Small Pharma, and Awakn Life Sciences are all currently conducting clinical trials on various psychedelic compounds, and the results so far are nothing short of astounding.
COMPASS Pathways and Awakn Life Sciences are particularly noteworthy, as they are both preparing to begin Phase 3 trials in the near future. COMPASS Pathways is testing a psilocybin formulation for treatment-resistant depression, while Awakn Life Sciences is testing ketamine for alcohol use disorder.
And then there's Rick Doblin, the Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS). Doblin is an industry expert who is among the increasing number of people who anticipate the FDA to take action on MDMA-assisted therapy in the near future. The future of psychedelic medicine is looking brighter than ever, and the possibilities are truly mind-blowing.
According to Doblin, MDMA-assisted therapy could potentially receive approval as early as April or May of 2024. This is a significant development as it would make MDMA, commonly known as ecstasy, a legal and accepted treatment option for individuals suffering from post-traumatic stress disorder (PTSD). MAPS has been at the forefront of research and advocacy for the use of psychedelics in therapy and medicine. With their prediction, it seems that the organization is optimistic about the progress being made towards the acceptance of MDMA-assisted therapy.
MDMA-assisted therapy has been gaining a lot of attention in recent years as a potential treatment for post-traumatic stress disorder (PTSD). PTSD is a debilitating condition that can occur after a person experiences a traumatic event, such as military combat, sexual assault, or a natural disaster. Symptoms can include flashbacks, nightmares, anxiety, and depression.
Current treatments for PTSD, such as cognitive-behavioral therapy and antidepressants, have been shown to be effective for some people, but not for everyone. As a result, there is a growing need for new and more effective treatments.
What is MDMA?
MDMA, also known as ecstasy or Molly, is a synthetic drug that has been used recreationally for its euphoric effects. However, recent research has shown that when used in a therapeutic setting, with trained therapists, MDMA can have a powerful therapeutic effect.
MDMA works by increasing the release of the neurotransmitters serotonin, dopamine, and norepinephrine in the brain. These neurotransmitters are involved in regulating mood, emotions, and social behavior. By increasing the release of these neurotransmitters, MDMA can help to reduce anxiety, increase empathy, and promote feelings of well-being.
In clinical trials, MDMA-assisted therapy has been shown to be effective in reducing symptoms of PTSD. In a study published in the Journal of Psychopharmacology, 83% of participants with PTSD who received MDMA-assisted therapy no longer met the criteria for PTSD after just two sessions. This is compared to 25% of participants who received a placebo.
Additionally, the benefits of MDMA-assisted therapy appeared to be long-lasting. In a follow-up study conducted 6-12 months later, 67% of participants who received MDMA-assisted therapy no longer had PTSD.
It is important to note that MDMA-assisted therapy is not without risks. MDMA can cause adverse effects such as anxiety, paranoia, and high blood pressure. It is important that the therapy is conducted under the supervision of trained therapists in a controlled setting.
As the Director of Maps, Rick Doblin, predicted, MDMA-assisted therapy is expected to be approved by the FDA for the treatment of PTSD by April/May of 2024. This would be a significant breakthrough in the treatment of PTSD and could help to improve the lives of millions of people.